Loading clinical trials...
Loading clinical trials...
A Short-term 12-Week, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled Study to Evaluate the Treatment Effect of Saxagliptin Compared With Placebo in Adult Patients With Type 2 Diabetes and Renal Impairment (Moderate, Severe, and End-Stage) With an Additional 40-week, Randomized, Double-blind, Placebo-controlled Long-term Observational Period.
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Research Site
Concord, California, United States
Research Site
Sacramento, California, United States
Research Site
Denver, Colorado, United States
Research Site
Topeka, Kansas, United States
Research Site
Baltimore, Maryland, United States
Research Site
Great Falls, Montana, United States
Research Site
Greenville, North Carolina, United States
Research Site
Morehead City, North Carolina, United States
Research Site
Cincinnati, Ohio, United States
Research Site
Corpus Christi, Texas, United States
Start Date
January 1, 2008
Primary Completion Date
June 1, 2009
Completion Date
March 1, 2010
Last Updated
May 19, 2011
572
ACTUAL participants
Saxagliptin
DRUG
Placebo
DRUG
Lead Sponsor
AstraZeneca
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06671587